FDA Leadership Shakeup: What Makary’s Exit Could Mean for the Nicotine Industry

The FDA is once again facing major leadership changes. 

After just 13 months leading the agency, FDA Commissioner Marty Makary is stepping down, according to administration officials. His departure follows months of reported internal tension, policy disputes, leadership turnover, and mounting criticism surrounding the agency’s direction. 

Kyle Diamantas will now step in as acting commissioner while the administration determines its next move. 

And for industries heavily impacted by FDA regulation — including vapor products and nicotine alternatives — the change could carry significant implications. 

 

A Turbulent Tenure 

 

Makary’s time at the FDA was anything but quiet. 

Reports surrounding his leadership described: 

• Internal policy clashes  
• Significant staff layoffs  
• High turnover among senior officials  
• Friction with lawmakers and industry stakeholders  
• Ongoing controversy surrounding FDA priorities and enforcement  

When asked directly whether Makary resigned or was fired, President Trump offered a notably careful response: 

“Well, I don't want to say... Everybody wants that job. It's a very important job... He's going to go on and lead a good life.” 

That answer alone has fueled speculation about how the administration viewed Makary’s performance behind closed doors. 

 

Why the Nicotine Industry Is Watching Closely 

 

For the vapor and nicotine pouch industries, FDA leadership matters enormously. 

The agency controls: 

• PMTA review decisions  
• Enforcement priorities  
• Marketing restrictions  
• Product authorization pathways  
• Future flavored product policy  

During Makary’s tenure, frustration within the independent nicotine industry continued to grow. 

Many manufacturers, retailers, and adult consumers criticized what they viewed as inconsistent enforcement, shifting standards, and a regulatory framework that often treated reduced-risk alternatives more aggressively than combustible cigarettes. 

At the same time, the FDA recently issued enforcement guidance stating it does not intend to prioritize enforcement against certain products with pending PMTAs — a notable shift that many believe should have happened years earlier. 

 

The Industry’s Biggest Concern: Regulatory Uncertainty 

 

Perhaps the biggest challenge facing the market today is uncertainty. 

Businesses have spent years trying to navigate: 

• PMTA application requirements  
• State registry laws  
• Flavor bans  
• Enforcement discretion policies  
• Rapidly evolving compliance expectations  

Meanwhile, many state governments have moved faster than the FDA itself, creating their own product registries and restrictions that are already reshaping the marketplace. 

For retailers and distributors, that creates a difficult environment where federal guidance and state law often move in completely different directions. 

 

What Could Change Under New Leadership? 

 

It is too early to know whether Kyle Diamantas will bring major policy changes to the FDA’s approach toward nicotine products. 

But the transition does create an opportunity for the agency to reconsider several critical issues, including: 

• Transparent PMTA standards  
• Consistent enforcement priorities  
• Science-based harm reduction policy  
• Clearer regulatory pathways for compliant products  
• A more balanced approach toward adult consumer access  

The FDA has recently shown signs that it may be willing to evolve its position, particularly with the historic authorization of certain non-menthol flavored ENDS products using advanced age-restriction technology. 

Still, many in the industry believe far more work remains. 

 

Harm Reduction Remains Central to the Debate 

 

One of the biggest ongoing tensions surrounding FDA policy is the role of tobacco harm reduction. 

Millions of adults have moved away from combustible cigarettes using alternatives like: 

• Open-system vapor products  
• Nicotine pouches  
• Closed-pod systems  
• Other smoke-free nicotine products  

Critics of the FDA’s past approach argue that regulations have too often failed to properly distinguish between combustible cigarettes and non-combustible alternatives. 

Supporters of harm reduction continue to push for policies that recognize relative risk while still preventing youth access. 

 

The Bottom Line 

 

Makary’s departure marks another major chapter in an already volatile period for the FDA. 

For the nicotine industry, the key question now becomes whether new leadership will bring: 

• Greater consistency  
• More transparent regulation  
• Improved scientific clarity  
• And a more practical balance between enforcement and harm reduction  

Because after years of uncertainty, many businesses and adult consumers are still waiting for a regulatory system that feels predictable, science-driven, and fair.